Colorectal cancer screening

In a cohort of 772,790 individuals aged 50-74 invited to the Scottish Bowel Screening Programme (2007-2009), screen-detected cancers (SCs) were diagnosed at significantly earlier stages than cancers in non-participants (NPCs): 33.9% of SCs were Dukes' A stage compared to only 11.3% of NPCs. There were 555 SCs, 502 interval cancers, and 922 NPCs identified by linking screening records with the Scottish Cancer Registry. The screening test sensitivity was approximately 50%, meaning that while screening misses some cancers, those it detects are caught at earlier, more favorable stages.

View Source →

Short-term pilot evaluation data from the 2011 CRC awareness campaign in two English regions showed increases in both GP attendances/referrals and CRC screening uptake. The mathematical model incorporating these screening uptake changes across England's population aged 30+ predicted 66 CRC deaths prevented and 404 QALYs gained over a lifetime horizon. The campaign cost £5.5 million with an incremental cost-effectiveness ratio of £13,496 per QALY, well below typical willingness-to-pay thresholds of £20,000-£30,000 per QALY used in England.

View Source →

A 22-year cohort study of 5,104 Chinese adults aged over 50 years compared outcomes between 3,863 screened participants and 1,241 non-screened participants. Annual three-tier fecal occult blood test screening reduced colorectal cancer incidence by 49% with relative risk 0.51 (95% CI, 0.30-0.87) and reduced mortality by 64% with relative risk 0.36 (95% CI, 0.18-0.71). The screening protocol demonstrated 80.6% sensitivity (95% CI, 65.3-91.1) for detecting colorectal cancer. Over the study period, 36 cancers occurred in the screening group versus 21 in the non-screening group, with significantly better survival outcomes in the screened population.

View Source →

Clinical guideline assigns Strength of Recommendation A to fecal occult blood testing for colorectal cancer screening, based on high-quality systematic reviews of randomized controlled trials (RCTs). FOBT demonstrated effectiveness in reducing mortality from colorectal cancer. The Grade A rating represents the highest level of clinical evidence confidence, derived from multiple well-designed RCTs synthesized through systematic review methodology.

View Source →

In a screening colonoscopy study of 2,210 consecutive average-risk adults, neoplastic lesions including 11 invasive cancers were found in 617 patients (27.9%). Advanced proximal neoplasms without any distal adenoma were present in 1.3% of patients. Of all advanced proximal lesions, 39% were not associated with any distal polyp. A strategy using distal findings as the sole indication for colonoscopy identified only 62% of advanced proximal neoplasms. Older age, male gender, and distal adenoma were independent predictors of advanced proximal neoplasms on multivariate logistic regression, though overall predictive ability remained relatively low.

View Source →